Harald Stenmark

A tentative title of my talk: "Cellular membrane dynamics and cancer"
- happy to participate in the career session.
The main research topic of HS has been to understand how alterations in cellular membrane dynamics promote cancer progression. A central contribution was his discovery of a conserved protein domain called the FYVE domain (Stenmark et al. Journal of Biological Chemistry,1996), which binds to the membrane lipid PI3P, the catalytic product of the tumour suppressor PIK3C3 (Gaullier et al., Nature, 1998). By identifying and characterizing a number of FYVE domain-containing PI3P binding proteins, HS and his co-workers have uncovered how PI3P recruits cytosolic proteins to specific intracellular membranes to control lysosomal degradation of growth factor receptors (Simonsen et al., Nature, 1998; Raiborg et al., Nature Cell Biology, 2002). This is important in order to understand the tumour suppressor function of PIK3C3 because lysosomal degradation of growth factors, mediated by the so-called ESCRT machinery, is a key mechanism to prevent overstimulation of cells by growth factors, a mechanism that is often inactivated in cancer (Raiborg and Stenmark, Nature, 2009). A further breakthrough was the identification of two PI3P-binding proteins that cooperate to control lysosome positioning and protrusion outgrowth, a topic of high relevance to cell signalling and cancer metastasis (Raiborg et al., Nature, 2015). The group of HS has also shown how PI3P-binding proteins regulate the final stage of cell division, cytokinesis, and demonstrated how their dysfunction can cause an abnormal number of chromosomes, a condition that promotes cancer development (Sagona et al., Nature Cell Biology, 2010; Thoresen et al., Nature Cell Biology, 2014). An important discovery was that the ESCRT machinery mediates sealing of the newly formed nuclear envelope during cell division, and that failure of this mechanism causes DNA damage, which is a driver of cancer progression (Vietri et al., Nature, 2015; received commentaries in both Nature and Science). This was followed up by a study showing that hyper-recruitment of ESCRT proteins to damaged micronuclei causes micronuclear catastrophe and chromosome damage (Vietri et al., Nature Cell Biology, 2020). Recently, the HS group co-discovered ESCRT-mediated mechanisms for repair of damaged lysosomes (Radulovic et al., 2018, EMBO Journal, 2018), and sealing of autophagosomes (Zhen et al., Autophagy, 2020).
  • 1991 - Dr.Philos., the Norwegian Radium Hospital, Faculty of Medicine, University of Oslo
  • 1985 - Cand. Pharm., School of Pharmacy, University of Oslo
  • 2018-now - Director Centre for Cancer Cell Reprogramming, University of Oslo
  • 2018-now - Head of Dept. Dept. of Molecular Cell Biology, Inst. for Cancer Research
  • 2007-now - Professor Faculty of Medicine, University of Oslo
  • 2004-now - Adjunct professor Inst. for Cancer Res. and Mol. Medicine, Univ. of Trondheim
  • 2016-2017 Act. Institute Head Institute for Cancer Research
  • 2009-2016 Head of Dept. Dept. of Molecular Cell Biology, Inst. for Cancer Research
  • 2007-2017 Director Centre for Cancer Biomedicine, University of Oslo
  • 1999-2003 Adjunct professor Department of Pharmacy, University of Oslo
  • 1997-2009 Group leader Department of Biochemistry, the Norwegian Radium Hospital
  • 1995-1997 Research fellow Department of Biochemistry, the Norwegian Radium Hospital
  • 1991-1994 Postdoc Cell Biology Programme, EMBL, Heidelberg
  • 1985-1991 Research assistant Department of Biochemistry, the Norwegian Radium Hospital
  • 2018 - Research Prize of the University of Oslo
  • 2015 - “Møbius” prize for outstanding research (Research Council of Norway)
  • 2014 - King Olav V’s Prize for cancer research (the Norwegian Cancer Society)
  • 2013 - Research Prize of Oslo University Hospital
  • 2010 - Sir Hans Krebs medal (Federation of European Biochemical Societies, FEBS)
  • 2002 - Research prize of the Norwegian Radium Hospital
  • 1999 - Anders Jahre’s prize for younger medical scientists in the Nordic countries
  • 1998 - Investigator of the Top Research Programme of the Research Council of Norway
  • 2016 - Elected member of the Royal Norwegian Academy of Science
  • 2011 - Elected member of the European Academy of Cancer Sciences
  • 2004 - Elected member of the Norwegian Academy of Science and Letters
  • 2002 - Elected member of the European Molecular Biology Organization (EMBO)